Karyopharm Therapeutics Inc.

Karyopharm Therapeutics is a commercial-stage pharmaceutical company focused on pioneering novel cancer therapies. Driven by a belief in the extraordinary strength and courage of cancer patients, the company develops oral drugs that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Their lead compound and first-in-class oral exportin 1 (XPO1) inhibitor, XPOVIO (selinexor), is approved in the U.S. and marketed by Karyopharm in three oncology indications. XPOVIO has also received regulatory approvals in various indications in a growing number of ex-U.S. territories and countries.

Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). Their commitment to supporting independent research is reflected in their Global Medical Research (GMR) program which provides drug supply and funding to eligible applicants. The company also offers an Expanded Access Program (KEAP) providing access to investigational medicines for patients who have exhausted all other treatment options.

Karyopharm Therapeutics offers employees flexibility in their work arrangements. They value a work environment that is supportive, flexible, and centered around a shared mission. They hire exceptional people and trust each other to work in whatever way lets them be their best, whether that's onsite, from home, or anywhere in between.

Karyopharm offers comprehensive employee benefits designed to support employee well-being and financial security. These benefits include health insurance, dental and vision coverage, telemedicine, and virtual reality options. The company also provides life and accidental death and dismemberment insurance for both employees and dependents, as well as short-term and long-term disability coverage. To support employee wellness, Karyopharm offers fitness reimbursement, mindfulness programs, exercise classes, and mental health programs. The company also provides a competitive 401k match with immediate vesting, an employee stock purchase program with a 15% discount, and a total rewards program.

Karyopharm Therapeutics is a commercial-stage pharmaceutical company dedicated to pioneering novel cancer therapies. Driven by a belief in the extraordinary strength and courage of cancer patients, Karyopharm is committed to developing and delivering life-changing treatments, particularly for those with high unmet needs, such as multiple myeloma, endometrial cancer, and myelofibrosis. Their focus on oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis, has led to the development of XPOVIO®, their first-in-class, oral exportin 1 (XPO1) inhibitor, which is currently approved in the U.S. and marketed in several oncology indications.

Karyopharm Therapeutics promotes a culture centered around support, flexibility, and a shared mission of pioneering novel cancer therapies. They prioritize a work environment where employees feel empowered to pursue their professional curiosities, are trusted to work in ways that best suit them, and feel like their work is making a meaningful impact on patients' lives. The company emphasizes a collaborative and supportive atmosphere built on their ICARE values - Innovation, Courage, Alignment & Accountability, Resilience, and Energy - fostering a team-oriented approach where employees can learn and grow alongside their colleagues.

Karyopharm Therapeutics is committed to diversity, equity, inclusion, and belonging, believing it strengthens the company and makes them uniquely suited to succeed in their mission of improving the lives of patients and their families. They celebrate all forms of diversity, including gender, gender identity, race, ethnicity, national origin, sexual orientation, differently-abled, veterans, and more. This commitment extends beyond just words, and is ingrained in their daily work, fostering a culture that values everyone's input and drives exceptional results.